Вторая линия лечения гепатоцеллюлярного рака: от теории к практике

СтатьяМЕД СОВЕТ. 2019; № 19: 30–36. DOI:10.21518/2079-701X-2019-19-30-36

Бредер В. В.^[1]

Лактионов К.К.^[1]

^[1]НИИ клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина

гепатоцеллюлярный рак

сорафениб-рефрактерный

ленватиниб

регорафениб

анти-PD1

ниволумаб

пембролизумаб

кабозантиниб

рамуцирумаб

гепатоцеллюлярная карцинома

ленватиниб

регорафениб

ниволумаб

пембролизумаб

кабозантиниб

рамуцирумаб

Карповые

Ниволумаб

Новообразования

Рамуцирумаб

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492..
DOI: 10.3322/caac.21492

Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf

NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, version 3.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf

Vogel A., Cervantes A., Chau I., Daniele B., Llovet J.M., Meyer T. et al; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018;29(Suppl.4):iv238–iv255. doi: 10.1093/annonc/mdy308..
DOI: 10.1093/annonc/mdy308

Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M., et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. doi: 10.1002/hep.29913..
DOI: 10.1002/hep.29913

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. doi: 10.1056/NEJMoa0708857..
DOI: 10.1056/NEJMoa0708857

Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7..
DOI: 10.1016/S1470-2045(08)70285-7

Lencioni R., Llovet J.M., Han G., Tak W.Y., Yang J., Guglielmi A., et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012..
DOI: 10.1016/j.jhep.2016.01.012

Meyer T., Fox R., Ma Y.T., Ross P.J., James M.W., Sturgess R., Stubbs C., et al: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5..
DOI: 10.1016/S2468-1253(17)30156-5

Bruix J., Takayama T., Mazzaferro V., Chau G.Y., Yang J., Kudo M., et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354. doi: 10.1016/S1470-2045(15)00198-9..
DOI: 10.1016/S1470-2045(15)00198-9

Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Piscaglia F., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1..
DOI: 10.1016/S0140-6736(18)30207-1

Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Cheng A.L., et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncology. 2019;37(4_suppl):186-186. doi: 10.1200/JCO.2019.37.4_suppl.186..
DOI: 10.1200/JCO.2019.37.4_suppl.186

Yau T., Park J.-W., Finn R.S., Cheng A.L., Mathurin P., Edeline J., et al. CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab vs Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. ESMO 2019, Barcelona. Annals of Oncology, 2019; 30(suppl_5):v851-v934. Available at: https://www.esmo.org/Oncology-News/NivolumabChallenges-Sorafenib-as-First-line-Treatmentin-Advanced-HCC.https://www.esmo.org/Oncology-News/NivolumabChallenges-Sorafenib-as-First-line-Treatmentin-Advanced-HCC

Bruix J., Qin S., Merle P., Granito A., Huang Y.-H., Bodoky G., Pracht M., et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9..
DOI: 10.1016/S0140-6736(16)32453-9

Finn R.S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69:353-358. doi: 10.1016/j.jhep.2018.04.010..
DOI: 10.1016/j.jhep.2018.04.010

Wilhelm S.M., Dumas J., Adnane L., Lynch M., Carter C.A., Schütz G., et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-255. doi: 10.1002/ijc.25864..
DOI: 10.1002/ijc.25864

Bekaii-Saab T.S., Ou F.S., Ahn D.H., Boland P.M., Ciombor K.K., Heying E.N., et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4..
DOI: 10.1016/S1470-2045(19)30272-4

Yakes F.M., Chen J., Tan J. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. doi: 10.1158/1535-7163..
DOI: 10.1158/1535-7163

Abou-Alfa G.K., Meyer T., Cheng A.L., El-Khoueiry A.B., Rimassa L., Ryoo B.Y., et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54-63. doi: 10.1056/NEJMoa1717002..
DOI: 10.1056/NEJMoa1717002

Spratlin J.L., Cohen R.B., Eadens M., Camidge D.R., Diab S., Leong S., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780–787. doi: 10.1200/JCO.2009.23.7537..
DOI: 10.1200/JCO.2009.23.7537

Zhu A.X., Park J.O., Ryoo B.-Y., Yen C.J., Poon R., Pastorelli D., et al. REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870. doi: 10.1016/S1470-2045(15)00050-9..
DOI: 10.1016/S1470-2045(15)00050-9

Zhu A.X., Kang Y.-K., Yen C.-J., Finn R.S., Galle P.R., Llovet J.M., et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36(15_suppl):4003-4003 doi: 10.1200/JCO.2018.36.15_suppl.4003..
DOI: 10.1200/JCO.2018.36.15_suppl.4003

Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi: 10.1016/S0140-6736(17)31046-2..
DOI: 10.1016/S0140-6736(17)31046-2

El-Khoueiry A.B., Melero I., Yau T.C., Crocenzi T.S., Kudo M., Hsu C., et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate 040. J Clin Oncol. 2018;36(4_suppl):475-475. doi: 10.1200/JCO.2018.36.4_suppl.475..
DOI: 10.1200/JCO.2018.36.4_suppl.475

Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D., et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open- label phase 2 trial. Lancet Oncol. 2018;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6..
DOI: 10.1016/S1470-2045(18)30351-6

Finn R.S., Ryoo B.-Y., Merle P., Kudo M., Bouattour M., Lim H.-Y., et al, for the KEYNOTE-240 Investigators; Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(suppl):abstr 4004. doi: 10.1200/JCO.2019.37.15_suppl.4004..
DOI: 10.1200/JCO.2019.37.15_suppl.4004

Wong D.J., Lee J., Choo S.P., Thng C.H., Hennedige T. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy. 2019;11(3):167–175. doi: 10.2217/imt-2018-0126..
DOI: 10.2217/imt-2018-0126

Alsina A., Kudo M., Vogel A., Cheng A.-L., Tak W.Y., Ryoo B.-Y., et al. Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. J Clin Oncol. 2019;37(4_suppl):371-371. doi: 10.1200/JCO.2019.37.4_suppl.371..
DOI: 10.1200/JCO.2019.37.4_suppl.371

Llovet J.M., Montal R., Sia1 Dand Finn R.S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599-616. doi: 10.1038/s41571-018-0073-4..
DOI: 10.1038/s41571-018-0073-4

Harding J.J., Nandakumar S., Armenia J., Khalil D.N., Albano M., Ly M., et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res. 2019;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293..
DOI: 10.1158/1078-0432.CCR-18-2293

Kudo M., Matilla A.M., Santoro A., Melero I., Gracian A.C., Acosta M.R., et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and ChildPugh B (CPB) status. J Clin Oncol. 2019;37(4_suppl):327-327. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.327.https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.327

European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001..
DOI: 10.1016/j.jhep.2011.12.001

Pishvaian M.J., Lee M.S., Ryoo B., Stein S., Lee K., Verret W., et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 2018;29. doi: 10.1093/annonc/mdy424.028..
DOI: 10.1093/annonc/mdy424.028

Xu J.M., Zhang Y., Jia R., Wang Y., Liu R., Zhang G., et al. Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial. J Clin Oncol. 2018;36:4075. doi: 10.1200/JCO.2018.36.15_suppl.4075..
DOI: 10.1200/JCO.2018.36.15_suppl.4075

Kelley R.K., Abou-Alfa G.K., Bendell J.C., Kim T.Y., Borad M.J., Yong W.P., et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol. 2017;35:4073. doi: 10.1200/JCO.2017.35.15_suppl.4073..
DOI: 10.1200/JCO.2017.35.15_suppl.4073

Ikeda M., Sung M.W., Kudo M., Kobayashi M., Baron A.D., Finn R.S., et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36:4076. doi: 10.1200/JCO.2018.36.15_suppl.4076.
DOI: 10.1200/JCO.2018.36.15_suppl.4076

Язык текста: Русский

ISSN: 2079-701X